William Blair Analysts Boost Earnings Estimates for BEAM

Key Points

• William Blair has revised its Q3 2025 earnings estimates for Beam Therapeutics, forecasting a smaller loss of ($0.87) per share, up from a previous estimate of ($0.93).
• Beam Therapeutics reported a loss of ($1.00) per share in its latest quarter, which was better than the consensus estimate of ($1.04).
• The company currently has a market capitalization of $1.81 billion and a consensus rating of "Buy" from analysts, with a target price of $48.45.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Analysts at William Blair increased their Q3 2025 EPS estimates for shares of Beam Therapeutics in a report issued on Tuesday, August 5th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($0.87) per share for the quarter, up from their previous estimate of ($0.93). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. William Blair also issued estimates for Beam Therapeutics' Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.94) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.93) EPS and FY2026 earnings at ($3.64) EPS.

A number of other research analysts also recently commented on BEAM. Wells Fargo & Company decreased their price objective on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Barclays decreased their price objective on shares of Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 6th. Guggenheim decreased their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Cantor Fitzgerald raised shares of Beam Therapeutics to a "strong-buy" rating in a report on Monday, July 21st. Two analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $48.45.

Beam Therapeutics Trading Down 1.4%

Shares of BEAM traded down $0.24 during midday trading on Friday, reaching $16.93. The stock had a trading volume of 1,836,804 shares, compared to its average volume of 2,052,646. The firm has a 50 day simple moving average of $18.86 and a 200-day simple moving average of $20.88. Beam Therapeutics has a one year low of $13.52 and a one year high of $35.25. The firm has a market cap of $1.71 billion, a PE ratio of -3.76 and a beta of 2.22.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($1.00) EPS for the quarter, beating analysts' consensus estimates of ($1.04) by $0.04. Beam Therapeutics had a negative net margin of 661.31% and a negative return on equity of 43.15%. The company had revenue of $8.47 million during the quarter, compared to the consensus estimate of $13.29 million. During the same quarter last year, the firm posted ($1.11) EPS. The company's quarterly revenue was down 28.0% on a year-over-year basis.

Insider Transactions at Beam Therapeutics

In other Beam Therapeutics news, insider Fmr Llc sold 48,374 shares of the business's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $20.50, for a total value of $991,667.00. Following the completion of the sale, the insider owned 2,073,665 shares of the company's stock, valued at $42,510,132.50. The trade was a 2.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 49,624 shares of company stock valued at $1,015,628. Insiders own 3.50% of the company's stock.

Institutional Trading of Beam Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Beam Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company's stock valued at $173,256,000 after purchasing an additional 1,249,303 shares during the period. ARK Investment Management LLC lifted its holdings in shares of Beam Therapeutics by 4.3% during the 2nd quarter. ARK Investment Management LLC now owns 8,847,841 shares of the company's stock worth $150,502,000 after acquiring an additional 367,752 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Beam Therapeutics by 0.4% during the 4th quarter. Farallon Capital Management LLC now owns 8,239,123 shares of the company's stock worth $204,330,000 after acquiring an additional 31,000 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Beam Therapeutics by 10.8% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,729,444 shares of the company's stock worth $80,448,000 after acquiring an additional 462,573 shares during the period. Finally, Nikko Asset Management Americas Inc. lifted its holdings in shares of Beam Therapeutics by 7.9% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 4,270,020 shares of the company's stock worth $83,265,000 after acquiring an additional 312,409 shares during the period. Institutional investors own 99.68% of the company's stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.